Cambridge, MA -- January 12, 2026

DaCapo Brainscience today announced the appointment of Leslie Williams as President and Chief Executive Officer (CEO), the appointment of Mridul Mehta, PhD, as Chief Technology Officer (CTO), and the promotion of Warren Hirst, PhD, to Chief Scientific Officer (CSO). DaCapo Brainscience is focused on applying its proprietary discovery platform – an in vitro model of neurodegenerative disease that recapitulates human biology – to identify and develop small molecule therapies capable of slowing or halting progression of neurodegenerative disease.

To view the full announcement, including downloadable images, bios, and more, click here.

• Biotech veteran Leslie Williams appointed as President & CEO to lead company through transition from early discovery to clinical-stage drug developer.
• Mridul Mehta, PhD announced as Chief Technology Officer and Warren Hirst, PhD promoted to Chief Scientific Officer.
• Strengthened leadership advances company goal to identify and develop small-molecule therapies to slow or stop neurodegenerative disease, beginning with Parkinson’s.

Click image above to view full announcement.

About DaCapo Brainscience

DaCapo Brainscience uses its own discovery platform to develop small-molecule medicines for neurodegenerative diseases. By combining advanced data analysis with human-based laboratory models, we identify new disease pathways and design targeted treatments that aim to slow or stop disease progression, with an initial focus on Parkinson’s disease.

Media and Investors
hello@dacapobrain.com

Source: DaCapo Brainscience

Distributed by: Reportable, Inc.

This contant was orignally distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is DaCapo Brainscience Appoints Leslie Williams as President & Chief Executive Officer; Announces Mridul Mehta, PhD, as Chief Technology Officer and Promotes Warren Hirst, PhD, to Chief Scientific Officer.